In January 2024, the FDA announced it was evaluating reports of hair loss and suicidal thoughts in patients taking Ozempic, Mounjaro and Wegovy
[17] Voiding symptoms include urinary hesitancy (a delay between trying to urinate and the flow actually beginning), intermittency (not continuous), [18] involuntary interruption of voiding, weak urinary stream, straining to void, a sensation of incomplete emptying, and uncontrollable leaking after the end of urination
These may include headaches, nausea, injection site reactions since its administered via a subcutaneous injection, water retention, and altered cortisol levels
Peptides: Epitalon, GHK-Cu, DSIP, Ipamorelin May help support recovery of joints, tendons, and soft tissue
MT-II operates via multiple G-protein coupled receptors to drive diverse physiological responses